FOXO TECHNOLOGIES INC. 8K

FOXO Technologies Inc.’s subsidiary Vector BioSource, Inc. agreed to acquire four U.S. blood collection centers from Grifols Bio Supplies, Inc. for cash plus a potential EBITDA-based earnout, aiming to add over $10 million in first-year revenues and expand its integrated biospecimen capabilities, with closing expected in Q3–Q4 2026 subject to regulatory approvals.

FOXO Technologies Inc., through its subsidiary Vector BioSource, Inc., has entered into a definitive asset purchase agreement with Grifols Bio Supplies, Inc., a U.S. subsidiary of Grifols S.A., to acquire four U.S.-based blood collection centers, with consideration consisting of an upfront cash payment and a potential earnout tied to EBITDA performance in 2026–2028. The transaction is expected to close in the third or fourth quarter of 2026, subject to customary conditions including obtaining new FDA licensure and other regulatory approvals, and management estimates the acquired centers could add over $10 million in net revenues in the first 12 months post-closing from sales of whole blood, packed red blood cells, serum and other biosamples. The acquisition is intended to transform Vector from a pure biospecimen sourcing company into a more integrated biospecimen solutions provider by securing a proprietary supply chain and expanding its addressable market through enhanced regulatory capabilities, while FOXO will be responsible for securing financing for the cash purchase price and faces execution, regulatory, and profitability risks as disclosed in its forward-looking statements.

Filing Facts

CIK

1812360

Ticker

-

Form

8K

Source Type

sec

Accession

0001493152-26-035110

Alert Tier

8